Everest Medicines' Partner Calliditas Therapeutics Made Presentations On Data From The Neflgard Phase 3 Study At The European Renal Association – European Dialysis And Transplant Association Congress
Portfolio Pulse from Benzinga Newsdesk
Everest Medicines' partner Calliditas Therapeutics presented data from the NefIgArd Phase 3 clinical trial at the European Renal Association Congress. The trial, evaluating Nefecon in patients with IgA nephropathy, met its primary endpoint with a highly significant benefit over placebo.
June 21, 2023 | 7:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Calliditas Therapeutics presented positive data from the NefIgArd Phase 3 clinical trial, which met its primary endpoint, showing a significant benefit of Nefecon over placebo.
The positive data from the NefIgArd Phase 3 clinical trial indicates that Nefecon is effective in treating patients with IgA nephropathy. This is likely to have a positive impact on Calliditas Therapeutics' stock price in the short term as it demonstrates the potential success of their product.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100